Jubilant Life Sciences announces price increase of 10% for Niacinamide
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated June 16, 2015 titled "Jubilant Life Sciences announces price increase of 10% for Niacinamide". Jubilants Spokane facility successfully concludes inspection status
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated June 12, 2015 titled "Jubilants Spokane facility successfully concludes inspection status". Code of Conduct of Fair Disclosure
Jubilant Life Sciences Ltd has informed BSE that the following :1. Jubilant Life Sciences Limited (the "Company") has formulated and published on its website, the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. A Copy of the Code is enclosed; and2. The Company has formulated a Code of Conduct for Prevention of Insider Trading. Clause 20
Jubilant Life Sciences Ltd has submitted to BSE a copy of Clause 20 of the Listing Agreement for the Financial Year ended March 31, 2015. Board recommends Dividend
Jubilant Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 12, 2015, has recommended a dividend of Rs.3/- (Rupees Three) per equity share of Re.1/- each for the year ended March 31, 2015. The dividend, if approved by the shareholders at the ensuing Annual General Meeting of the Company, will be paid / despatched on or before September 30,2015. Announces Q4 & FY15 results, Results Press Release, Presentation & Auditors' Report for the period ended March 31, 2015
Jubilant Life Sciences Ltd has announced the following results for the quarter & year ended March 31, 2015:The Audited results for the Quarter ended March 31, 2015The Company posted a net loss after taxes of Rs. (2068.90) million for the Quarter ended March 31, 2015 where as the same was at Rs. 207.60 million for the Quarter ended March 31, 2014. Total Income is Rs. 7468.60 million for the Quarter ended March 31, 2015 where as the... Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Jubilant Life Sciences Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
GA Global Investments Ltd has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 Funds' buying may boost Jubilant Life
East Bridge Cap MTR Fund and Morgan Stanley (Singapore) each bought 60 lakh shares and 27.29 lakh shares of Jubilant Lifesciences on Tuesday, according to NSE bulk deal data. They bought t...